Sichuan Kelun Pharmaceutical Co., Ltd. Class A
002422
Kedudukan dalam Saham
#2010
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and... Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Harga Saham
$6.40
Modal Pasaran
$10.19B
Perubahan (1 hari)
-0.77%
Perubahan (1 tahun)
27.14%
Negara
CN
Perdagangan Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Kategori
Healthcare
Nisbah P/E bagi Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Nisbah P/E pada October 2026 TTM: 36.86
Menurut laporan kewangan dan harga saham terkini Sichuan Kelun Pharmaceutical Co., Ltd. Class A, nisbah P/E semasa (TTM) ialah 36.86. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 16.09.
Sejarah nisbah P/E bagi Sichuan Kelun Pharmaceutical Co., Ltd. Class A dari 2007 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 36.86 | 34.39% |
| 2025 | 27.43 | 70.46% |
| 2024 | 16.09 | -7.22% |
| 2023 | 17.34 | -20.64% |
| 2022 | 21.85 | -9.95% |
| 2021 | 24.27 | -27.59% |
| 2020 | 33.52 | -5.83% |
| 2019 | 35.59 | 50.06% |
| 2018 | 23.72 | -48.32% |
| 2017 | 45.89 | 16.72% |
| 2016 | 39.32 | -4.88% |
| 2015 | 41.33 | 97.90% |
| 2014 | 20.89 | 2.38% |
| 2013 | 20.40 | -17.32% |
| 2012 | 24.67 | 14.25% |
| 2011 | 21.60 | -57.77% |
| 2010 | 51.14 | 35.77% |
| 2009 | 37.66 | -26.47% |
| 2008 | 51.22 | -26.86% |
| 2007 | 70.03 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 30.83 | -16.36% |
US
|
|
| -29.16 | -179.11% |
US
|
|
| -25.99 | -170.51% |
AU
|
|
| 22.43 | -39.14% |
BE
|
|
| 31.22 | -15.31% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.